for preliminary approval of a settlement agreement
that provides class members with a 30 percent cash refund of the company’s suggested retail price for Prevagen products. Class members with proof of purchase may receive a maximum award of $70 while class members without proof of purchase may receive a maximum award of $12. The company also agreed to stop marketing that Prevagen improves memory without adequate scientific evidence to support such claims or qualifying the advertising claim with a disclaimer. This settlement resolves seven lawsuits: Collins
, and Vanderwerff
, as well as one state case Miloro v. Quincy Bioscience
April 2019: The Spath case was transferred to a court in New York. (Case No. 19-cv-3521, S. D. NY.)
October 2018: The parties agreed to consolidate this case with Vanderwerff v. Quincy Bioscience (Case No. 17-cv-784, D. NJ.), which will be the lead case.
August 2018: A class-action lawsuit was filed against Quincy Bioscience for allegedly falsely marketing the supplement Prevagen as being clinically tested to improve memory within 90 days and support “healthy brain function, sharper mind, and clearer thinking” when, according to plaintiffs, the supplement has not been clinically tested and does not provide the advertised brain and memory benefits. (Spath et al v. Quincy Bioscience Holding Company, Inc. et al, Case No. 18-cv-12416, D. NJ.)
For more of TINA.org’s coverage of Prevagen, click here.